BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 26 September 2013 at 9.00 a.m. Biotie: Selincro enters the market in Italy Biotie today announced that its partner H.Lundbeck A/S (Lundbeck) has brought Selincro on the market in Italy. According to the terms of the license agreement between Biotie and Lundbeck for Selincro, Biotie is eligible for a milestone payment of EUR 2 million related to the market entry. Lundbeck will continue the rollout of Selincro in additional European markets through 2013 and into 2014. Turku, 26 September 2013 Biotie Therapies Corp. Timo Veromaa President and CEO For further information, please contact: Virve Nurmi, Investor Relations Manager tel. +358 2 274 8900, e-mail: virve.nurmi@biotie.com Distribution: NASDAQ OMX Helsinki Ltd Main Media www.biotie.com ABOUT SELINCRO (nalmefene): Selincro is indicated for the reduction of alcohol consumption in adult patients with alcohol dependence who have a high drinking risk level (>60 g/day for men, >40 g/day for women) without physical withdrawal symptoms and who do not require immediate detoxification. Selincro should be prescribed in conjunction with continuous psychosocial support focused on treatment adherence and the reduction of alcohol consumption. Treatment should be initiated only in patients who continue to have a high drinking risk level two weeks after an initial assessment. Selincro is to be taken as-needed; that is, on each day the patient perceives a risk of drinking alcohol, one tablet should be taken, preferably 1-2 hours prior to the anticipated time of drinking. Biotie has licensed global rights to Selincro to Lundbeck. Under the terms of the agreement, Biotie is eligible for up to EUR 89 million in upfront and milestone payments plus royalties on sales of Selincro. Upon payment of the milestone for market entry in Italy, Biotie will have received EUR 16 million of such milestone payments from Lundbeck. Further payments of EUR 2 million are expected on commercial launch of Selincro in each of France, Germany and Spain, and further potential milestone payments on launches in certain other markets and if the product reaches certain predetermined sales. In addition, Biotie will continue to receive royalties on sales in all launched markets and make a contribution to Lundbeck towards any required post approval commitments studies, neither of which are expected to have a significant financial impact in 2013. Lundbeck is responsible for the registration, manufacturing and marketing of the product. ABOUT BIOTIE Biotie is a specialized drug development company focused primarily on products for neurodegenerative and psychiatric disorders. For the past years, Biotie has successfully operated a strategy built around search, profile and partner. This has delivered Selincro (nalmefene) for alcohol dependency, which received European marketing authorization in February 2013 and is currently being rolled out across Europe by partner H. Lundbeck A/S, and tozadenant, a novel A2a antagonist which is transitioning into Phase 3 development for Parkinson's disease in collaboration with UCB Pharma S.A.. Biotie also has exclusive rights through an option to acquire Neurelis Inc., which includes NRL-1, an intranasal formulation of diazepam for epileptic seizure management. Biotie plans to seek further opportunities of this kind to generate a strong portfolio of products. Biotie's shares are listed on NASDAQ OMX Helsinki. [HUG#1731499]
Biotie: Selincro enters the market in Italy BIOTIE
Top 10 Most Recent News Articles
Phase I of 2026 Hong Kong Trade Shows Highlights Innovation
Hong Kong Takes Center Stage in Global Commerce Flip through the economic landscape today, and you’ll spot Hong Kong, decked out in its best as a trade linchpin—with over 2,100 suppliers gathered under one roof. AsiaWorld-Expo is buzzing with the commencement of Phase I of the October 2026 Global Sources Hong Kong Shows. The theme's all about 'Connecting Global...
Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight
First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...
Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances
A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...
Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps
Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...
Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight
A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...
Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity
Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...
Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data
Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...
Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal
A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...
Continue Reading
NARUTO Card Game Set for June 2027 Global Launch
Mark Your Calendars: Global Launch June 2027 They're rolling out a red carpet for nostalgia here, I tell ya! At the New York Comic Con, BANDAI announced a worldwide launch for the NARUTO CARD GAME in June 2027. We'll see pre-built decks starring your favorite shinobi and a mad sprint to collect with the new booster packs. Feels sort of like they’re summoning a jutsu...
Continue Reading
AI Drives Major Time Savings in Endoscopy Tech
AI in Endoscopy: Game-Changer or Gimmick? Stumbling across AnX Robotica's latest pitch about their NaviCam ProScan AI workflow, one can't help but feel a mix of curiosity and skepticism. With the stakes in medical tech sky-high, they've fired off some impressive stats that grab attention. We're talking about cutting small-bowel capsule review times by a whopping...
Continue ReadingTop 5 Most Recently Viewed Articles
Celebrating Culture and Excellence at Clark Capital Management
Clark Capital Management Group Achieves Excellence in Workplace Culture Clark Capital Management Group has once again demonstrated its commitment to creating an outstanding workplace culture. For the seventh consecutive year, the company has been acknowledged by the Philadelphia Business Journal as one of the best places to work in the large-size firm category. This...
Continue Reading
OpenAI Partners with Freedom Holding to Enhance Education in Kazakhstan
OpenAI and Freedom Holding Corp. Join Forces in Kazakhstan The recent partnership between OpenAI, Inc. and Freedom Holding Corp. (NASDAQ: FRHC) marks a transformative moment in Kazakhstan's educational landscape. This strategic agreement paves the way for 165,000 educators across the nation to access ChatGPT Edu, a tailored educational version of ChatGPT, enriched with...
Continue Reading
InnSuites Hospitality Trust Achieves Significant Stock Milestone
InnSuites Hospitality Trust Stock Surges to New Heights In an impressive demonstration of market resilience, InnSuites Hospitality Trust (IHT) has recently achieved a significant milestone, reaching a 52-week high of $2.36. This notable peak signifies more than just a numerical rise; it highlights the confidence and optimism investors have in the hospitality sector's...
Continue Reading
Adrian Kreter's Bold Move with Annanow Enhances Growth Potential
Exciting New Horizons for Annanow with Adrian Kreter's Acquisition In an impressive strategic investment, Swiss technology company Annanow has been fully acquired by entrepreneur Adrian Kreter. This acquisition marks a significant step forward for Annanow as it aspires to reshape its place in the omnichannel technology landscape. With its roots established in 2017,...
Continue Reading
Credit Acceptance Expands Senior Notes Offering to $500 Million
Credit Acceptance Prices $500 Million Senior Notes Offering Credit Acceptance Corporation (Nasdaq: CACC) has announced a significant milestone in its financing strategy, pricing an aggregate principal amount of $500 million for its recently issued 6.625% senior notes due 2030. This offering not only reflects the company’s confidence in its financial future but also...
Continue Reading